GSK Announces Positive Topline Data on Co-Administration of …
WEB3 days ago · PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity ...
GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB3 days ago · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
GSK Meets Study Goal for Co-Administered RSV-Shingles Vaccines
WEB2 days ago · Written by Zacks Equity Research for Zacks ->. GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine ...
Press releases - GSK
WEBFind out the latest news and updates from GSK, a global healthcare company, on its products, pipeline, partnerships and performance. See the list of press releases from July to August 2024, covering topics such as RSV vaccine, Zantac litigation, HIV …
GSK plc (GSK) Latest Stock News & Headlines - Yahoo Finance
WEBGet the latest news and updates on GSK plc (GSK), a global pharmaceutical company based in the UK. See how GSK performed in Q2 2024, its dividend policy, its vaccine sales, its legal issues,...
GSK antibody drug reduces COPD attacks in trial
WEBSep 6, 2024 · Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive pulmonary disease, offering the British drugmaker another shot at an expanded approval for the drug. The trial, known as MATINEE, included COPD patients suffering from chronic bronchitis …
GSK.L - | Stock Price & Latest News | Reuters
WEBSep 15, 2024 · Get GSK plc (GSK.L) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.
GSK shares fall as US narrows age recommendation for RSV vaccines
WEBJun 27, 2024 · GSK shares fell more than 6 per cent on Thursday morning after US health officials recommended restricting the use of vaccines for respiratory syncytial virus, an area in which the British ...
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or ...
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
Skip to content